Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

CONCLUSION: Per DLT criteria, binimetinib + pembrolizumab (cohort A) was tolerable, binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, oxaliplatin (cohort C) did not qualify for binimetinib dose escalation to 45 mg, and binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, irinotecan (cohort E) required binimetinib dose reduction from 45 to 30 mg. No new safety findings were observed across cohorts. There was no apparent additive efficacy when binimetinib + pembrolizumab was added to chemotherapy. Data did not support continued enrollment in cohorts C and E.PMID:38653648 | DOI:10.1016/j.clcc.2024.03.002

Source: Clinical Colorectal Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Eric X Chen Petr Kavan Mustapha Tehfe Jeremy S Kortmansky Michael B Sawyer E Gabriela Chiorean Christopher H Lieu Blase Polite Lucas Wong Marwan Fakih Kristen Spencer Jorge Chaves Chenxiang Li Pierre Leconte David Adelberg Richard Kim Source Type: research